PROfesy CR enables pharmaceutical companies to:

• forecast, in the lead up to patent expiry, future post-patent expiry prices.

• manage pricing post-generic launch.

In either case, the flexibility of PROfesy CR allows the potential impact of a variety of “what-if” scenarios to be measured.

A good example of this would be with reference to the number of licence-holders actively competing, or expected to compete, in a given market.

Users can run a sequence of forecasts, changing the variables of both no. of competitors and when they enter (or leave) the market, and compare the effect on the forecasted future prices.

A further variable which can have a pronounced impact on the market price is the level of reimbursement.

This has particular significance here in the UK since the inception of the generic Category M of the Drug Tariff in 2005.

Our observations have shown that about 1/3rd of new generic products had been integrated into Category M within 3 to 6 months after introduction, while a further 50% were included by about 9 months after launch.

Manufacturers can use PROfesy CR to observe the effect on future prices of these alternative time scales.

When either gentle or more significant decreases in the reimbursement price are also modelled, a complete matrix of potential results can be depicted, thus aiding the fine-tuning of marketing strategies and budgetary plans.